Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the food and drug administraton summary basis of approval reports

Neuropsychopharmacology

Volumn 28, Issue 3, 2003, Pages 552-557

  Khan, Arif ^a,b   Khan, Shirin R ^a   Walens, Gary ^c   Kolts, Russell ^d   Giller, Earl L ^c,e  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d EASTERN WASHINGTON UNIVERSITY   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Clinicaltrials; Fixed dose; Flexible dose; Meta analysis; Placebo

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG APPROVAL; HUMAN; MAJOR DEPRESSION; META ANALYSIS; PSYCHOLOGICAL ASPECT; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

ANTIDEPRESSIVE AGENTS; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; HUMANS; TREATMENT OUTCOME; UNITED STATES;

EID: 0038014050     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300059     Document Type: Article

References (9)

1. Benkert O, Szegedi A, Wetzel H (1996). Minimum effective dose for the antidepressants—an obligatory requirement for antidepressant drug evaluation? IntClinPsychopharmacol 11: 177-185.
2. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C (1999). Effectiveness of antidepressants. Meta-analysis of dose effect relationships in randomized clinical trials. Br J Psychiatry 174: 297-303.
3. US Congress (1996).Freedom of Information Act. 5 US Congress. 552 (1994 & Supp. II 1996).Available at http://www.usdoj. gov/04foia/. Accessed January 21, 1999. Br J Psychiatry 174: 297-303.
4. Gram LF (1990).Inadequate dosing and pharmacokinetic varia-bility as confounding factors in assessment of efficacy of antidepressants. ClinNeuropharmacol 3: S35-44.
5. Khan A, Khan S, Leventhal R, Brown WA (2001). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the food and drug administration database. Int J Neurosychopharmacol 4: 113-118.
6. Khan A, Warner HA, Brown WA (2000). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration Database. Arch Gen Psychiatry 57: 311-317.
7. Montgomery SA (1995). Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram. IntClin Psychopharmacol 10: 23-27.
8. Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Pioux P (1994). The optimal dosing regimen for citalopram—a metaanalysis of nine placebo-controlled studies. IntClinPsychopharmacol 9: 35-40.
9. Schatzberg AF (1991). Dosing strategies for antidepressant agents. J Clin Psychiatry 52: S14029.